Flamma Continues Veklury Partnership with Gilead for Covid-19

Flamma entered into an agreement with Gilead earlier this year to be part of the network of manufacturers contributing to the Veklury® (remdesivir) supply chain. Flamma will continue to use its sites in Italy and China to support the need for necessary compounds in an effort to help COVID-19 patients in need.

“Covid-19 hit very close to home as Flamma is located in the Bergamo, one of the most affected areas in Italy. Our facility in Dalian, China remained in full operation after the extended Chinese New Year after adding proper precautions to protect the safety and health of its employees,” said Gian Paolo Negrisoli, CEO. “Our Italian team members utilized the protocols learned from our Chinese team and instituted them in Italy. This allowed our teams there to continue to support our customers with little to no interruption to the supply chain”.

Flamma has worked to provide continuous manufacturing support for remdesivir, maintaining timelines for current and upcoming projects due to the global and local needs.

“This pandemic brought forth many challenges but Flamma responded to all of them with dedication and a team spirit by working tirelessly to be a part of the pharmaceutical supply chain to help those in need” said Kenneth Drew, Ph.D., VP Flamma, USA.

During the Covid-19 crisis, Flamma teams in Italy and China have continued production of important molecules that are critical to help fight the virus.

Veklury (remdesivir) is an investigational nucleotide analog developed by Gilead, building on more than a decade of the company’s antiviral research. Multiple ongoing international Phase 3 clinical trials are evaluating the safety and efficacy of Veklury for the treatment of COVID-19. Based on available data from these studies, Veklury has been approved or authorized for temporary use as a COVID-19 treatment in approximately 50 countries worldwide.

Additional ongoing international clinical trials continue to further evaluate the safety and efficacy of Veklury in different patient populations and formulations, and in combination with other therapies.